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Abstract
We evaluated micro (mi) RNA-mediated regulation of BAFF expression in fibroblasts using two concomitant models: (i)
synovial fibroblasts (FLS) isolated from healthy controls (N) or Rheumatoid Arthritis (RA) patients; (ii) human dermal
fibroblasts (HDF) isolated from healthy controls (N) or Systemic Sclerosis (SSc) patients. Using RT-qPCR and ELISA, we first
showed that SScHDF synthesized and released BAFF in response to Poly(I:C) or IFN-c treatment, as previously observed in
RAFLS, whereas NHDF released BAFF preferentially in response to IFN-c. Next, we demonstrated that miR-30a-3p expression
was down regulated in RAFLS and SScHDF stimulated with Poly(I:C) or IFN-c. Moreover, we demonstrated that transfecting
miR-30a-3p mimic in Poly(I:C)- and IFN-c-activated RAFLS and SScHDF showed a strong decrease on BAFF synthesis and
release and thus B cells survival in our model. Interestingly, FLS and HDF isolated from healthy subjects express higher levels
of miR-30a-3p and lower levels of BAFF than RAFLS and SScHDF. Transfection of miR-30a-3p antisense in Poly(I:C)- and IFN-
c-activated NFLS and NHDF upregulated BAFF secretion, confirming that this microRNA is a basal repressors of BAFF
expression in cells from healthy donors. Our data suggest a critical role of miR-30a-3p in the regulation of BAFF expression,
which could have a major impact in the regulation of the autoimmune responses occurring in RA and SSc.
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Introduction
TNFSF13B (also known as B cell-activating factor -BAFF,
which will be the only nomenclature used thereafter in the
manuscript) is a member of the TNF superfamily which plays a
central role in the survival and homeostasis of transitional and
naive B cells, plasmablasts and plasma cells [1]. BAFF is produced
as a membrane-bound form or secreted by cells of hematopoietic
origin, essentially monocytes, dendritic cells, macrophages and
stimulated neutrophils [2,3]. However non-immune cells, such as
astrocytes, can also constitutively produce BAFF [4].
The finding that BAFF transgenic mice develop autoimmune
manifestations exhibiting similarities with systemic lupus erythe-
matosus (SLE) and Sjo¨gren’s syndrom (SS) suggested a critical role
for this cytokine in autoimmune diseases [5–7]. Consistent with
this observation, auto-reactive B cells have a greater dependency
for BAFF compared to naive mature B cells and elevated levels of
BAFF were detected in the serum of patients with SLE,
rheumatoid arthritis (RA) and SS [8]. In addition, these increased
BAFF levels correlated with high auto-antibody titers and disease
activity [9]. In patients with systemic sclerosis (SSc), increased
levels of BAFF were associated with worsening of the skin sclerosis
[10,11]. Similar results were obtained in experimental arthritis
where overproduction of BAFF by dendritic cells and macro-
phages was demonstrated to play a crucial role in the disease [12].
Fibroblast-like synoviocytes isolated from RA patients (RAFLS)
are characterized by their aggressive phenotype in response to
various stimuli. In these inflammatory conditions, these cells also
produce large amounts of cytokines including BAFF, thus enabling
them to collaborate with autoimmune B cells [13]. Altogether,
these data illustrate the central role played by BAFF in the
pathogenesis of autoimmune diseases, which prompted the
development of biological agents targeting BAFF. Belimumab, a
humanized IgG1 monoclonal antibody which inhibits both soluble
and membrane BAFF binding to BAFFR and TACI, was
approved for the treatment of SLE [14–16].
However, modulation of BAFF activity for therapeutic purposes
by targeting its synthesis has not yet been considered. The control
of cytokine expression can occur at various levels including post-
transcriptional regulation, which is now the focus of intense
attention. The modulation of gene expression can take place at
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several levels, among which regulation by microRNAs (miRNAs)
has gained increased interest in the recent years. MiRNAs are an
evolutionarily conserved class of endogenous small non-coding
RNAs. They are produced from long precursor molecules by the
consecutive action of the RNase III enzymes DROSHA and
DICER, before being loaded on an ARGONAUTE protein
within the RNA-induced-silencing complex (RISC). The mature
miRNA acts a guide for RISC to mediate destabilization and/or
translational repression of target mRNAs. The regulation of
miRNA expression is itself controlled at various levels such as
transcription, processing or stability and can be influenced by
various stress factors including inflammation. In addition, emerg-
ing data have identified an important contribution of miRNA to
the development and control of the inflammatory response which
position these small non-coding RNAs at the heart of feedback and
feed-forward loops controlling the inflammation process in both
immune and non immune cells. Recently, microRNAs (miRNAs)
have emerged as a new class of cytokines regulators, although
computational analysis indicates that the 39UTR (Three prime
untranslated region) of many cytokines lacks miRNA target sites.
Indeed, miRNAs could also regulate cytokine expression by
targeting ARE-binding proteins (ARE machinery components)
such as TTP, AUF1 and members of the HuR family [17,18].
In this study, we found that miR-30a-3p (and miR30d-3p and e-
3p, which exhibit high sequence homology) is predicted to bind
the 39UTR region of BAFF transcripts. In SSc patients, we
observed concomitant up-regulation of BAFF transcripts and
decreased expression of miR-30a-3p in skin fibroblasts (HDF)
isolated from SSc patients after cell stimulation with Poly (I:C) or
IFN-c. Analysis of synovial fibroblasts from RA patients yielded
similar results. The prediction provided by bioinformatic tools and
this inverse correlation between miR-30 family members and
BAFF expression prompted us to analyze their likely direct
interaction. To this end, we used reporter constructs containing a
luciferase gene fused to the wild type or mutated full length human
BAFF 39UTR. Co-transfection of these reporter plasmids with
miRNA mimic in cultured cells confirmed direct interaction.
Furthermore, transfection of miR-30a-3p mimic or inhibitor in
fibroblasts isolated from the skin or the synovium of healthy
donors or from patients confirmed that this miRNA modulate
IFN-c- and Poly (I:C)-dependent BAFF expression. Finally, we
report that miRNA-modulated BAFF secretion by activated skin
or synovial fibrocytes significantly reduces the capacity of these
cells to promote B cells survival, which provides physiological
significance to our findings. Altogether, our data describe a novel
mechanism involved in the regulation of BAFF expression and
potentially provide an additional level of intervention for future
therapeutic purposes.
Materials and Methods
Reagents
Cell culture media (RPMI 1640, M199 and DMEM), fetal calf
serum (FCS), L-glutamine, penicillin, streptomycin, amphotericin
B, TRIzol reagent and DiOC6 (3,39-Dihexyloxacarbocyanine
Iodide) were from Invitrogen (Cergy-Pontoise, France). LPS from
Salmonella abortus equi and Propidium Iodide (PI) solution was
obtained from Sigma Aldrich (Saint-Quentin-Fallavier, France).
Synthetic bacterial lipopeptide Pam3CSK4 (BLP) was obtained
from EMC Microcollections GmbH (Tuebingen, Germany).
Polyinosine-Polycytidylic acid (Poly(I:C)) was obtained from
InvivoGen (Toulouse, France). iScript cDNA Synthesis Kit and
SsoAdvanced SYBR Green Supermix from Bio-Rad (Marnes-la-
Coquette, France). The miScript System, miRNA mimc and
Allstars negative control siRNA were obtained from Qiagen
(Courtabeuf, France). miR-30a-3p antagonists were from Fisher
scientific (Illkirch Cedex, France). Human Dermal Fibroblast
Nucleofector kit was from Lonza (Cologne, Germany). The
enzyme immunoassay kits for human BAFF, APRIL and IL-6
detection and recombinant IFN-c were from R&D systems (Lille,
France).
Cell culture
Human FLS were isolated from synovial tissues from five
different RA patients and from five healthy subjects at the time of
knee joint arthroscopic synovectomy. RA patients were 3 female
and two male, the average age is 49 years, and had all FR positive
but only three were antiCCP positive. Human dermal fibroblasts
(HDF) were obtained by biopsy of 4 mm diameter from the
affected areas (dorsal forearm) of four patients with SSc
(SScHDF)and from the corresponding area of three healthy
subjects (NHDF). All SSc patients were female (average age52
years) and had diffuse cutaneous systemic sclerosis and anti-Scl70-
positive antibodies. The total modified Rodnan skin scores were
29, 8, 25 and 14, and that for the biopsy area were 2, 1, 2, 2.Blood
B cells were isolated from 6 healthy donors. Institutional ethics
committee of the Hopitaux Universitaires de Strasbourg specifi-
cally approved this study.Written informed consent was obtained
by all the participants of this study (patients and healthy donors).
The diagnosis of RA and SSc was conformed to the revised criteria
of the American College of Rheumatology (ACR). FLS, HDF and
HEK293 cultures were done as previously described [19].
Experiments were performed between the 3rd and the 9th passage.
During that time, cultures were constituted of a homogeneous
population of fibroblastic cells, negative for CD16 as determined
by FACS analysis. HEK293 cells were purchased from the
American type culture collection (ATCC) and maintained in
DMEM supplemented with 10% heat-inactivated FBS, 2 mM of
L-glutamine, 40 U/ml penicillin and 50 mg/ml streptomycin.
Cell number and cell viability were checked by the MTT (3-(4,5
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay.
Blood mononuclear cells were isolated from healthy blood donors
by Ficoll-Paque centrifugation as described in standard protocols.
B cells were then selected by negative sorting using EasySep
Human B Cell Enrichment Kit (Stemcell Technologies). The
efficacy of B cell isolation was determined by FACS analysis using
anti-CD19 antibodies. The yield of isolated B cells was composed
of 99% CD19+/CD32 B cells and 0.01% of CD192/CD3+ T
cells.
Stimulation of cells for total RNA extraction
FLS (2.105 cells) and HDF (2.105 cells) were seeded in 24-well
plates and stimulated with medium alone or medium containing
LPS (1 mg/mL), BLP (1 mg/mL), Poly(I:C) (10 mg/mL) and IFN-c
(0.1, 1 or 5 ng/mL). After a 6 h, 48 h and 72 h incubation period,
total RNA was extracted using TRIzol according to the
manufacturer’s instruction.
Real-time quantitative PCR (RT-qPCR)
Total RNA was reverse transcribed using the iScript cDNA
Synthesis Kit according to the manufacturer’s instructions
(BioRad). Real-time quantitative RT-qPCR was performed in a
total volume of 20 mL using SsoAdvanced SYBR Green Supermix
(BioRad) and gene-specific primers: BAFF: 59-TGAAACAC-
CAACTATACAAAAAG-39 and 59-TCAATTCATCCCCAAA-
GACAT-39;
April: 59- CTCTGCTGACCCAACAAACA-39 and 59-
CTCCTTTTCCGGGATCTCTC-39;
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Gapdh: 59-GGTGAAGGTCGGAGTCAACGGA-39 and 59-
GAGGGATCTCGCTCCTGGAAGA-39
After an initial denaturing at 96uC for 10 min, the temperatures
used were 95uC for 10 s, 60uC for 15 s, 72uC for 25 s using a
Rotor-Gene 6000 real-time PCR machine (Corbett Life Science).
Amplification products were detected as an increased fluorescent
signal of SYBR Green during the amplification cycles. Results
were obtained using Rotor-Gene 6000 Series Software and
evaluated using Excel (Microsoft). Melting-curve analysis was
performed to assess the specificity of PCR products.
Real-time quantitative PCR analyses for miRNAs were
performed using the miScript System and the primers (Qiagen).
RNA concentrations were determined with a NanoDrop instru-
ment (NanoDrop Technologies). 500 ng of RNA per sample was
used for the assays. Reverse transcriptase reactions and RT-qPCR
were performed according to the manufacturer’s protocols.
Expression of endogenous U6snRNA was used for normalization.
Relative expression was calculated using the comparative thresh-
old cycle (Ct) method and fold induction in cells activated by
Poly(I:C) or IFN-c was obtained by calculating 22DDCt.
Transfections and luciferase assay
Transient transfection of FLS or HDF with miR-30a-3p mimic
(20 pM/sample), miR-30a-3p antagonists or with the negative
controls was performed using the Human Dermal Fibroblast
Nucleofector kit from Lonza as previously described [20].
Transfection of HEK293 cells was performed using Lipofectamine
2000 (Invitrogen) as previously described [19].
B cells viability assay
FLS or HDF were transfected with miR-30a-3p mimic, miR-
30a-3p antagonists or with the negative controls as described
above and stimulated with medium alone or medium with
Poly(I:C) (10 mg/mL) or IFN-c (5 ng/mL) for 72 h. Supernatants
(800 mL) were harvested and used to culture B cells (56105) for
72 h. In some experiments, anti-human BAFF antibodies or
control IgG (R&D Systems) were added (10 ng/mL) to the
supernatant. Then, B cells were stained with 3,3-dihexyloxacar-
bocyanine iodide (DiOC6) to assess the mitochondrial transmem-
brane potential, and with Propidium Iodide (PI) to assess
membrane permeability, as described [21]. Briefly, cell suspen-
sions were incubated with 40 nmol/L DiOC6 and 1 mg/ml PI for
15 min at 37uC, washed with FACS buffer and then analyzed on
FACSCalibur (BD Biosciences). A lymphocyte gate was set using
forward-angle and side-angle light scatter characteristics of
lymphocytes. The vital B cells were brightly positive when stained
with DiOC6 and excluded PI.
Statistical analysis
Student’s t test (two-tailed unpaired) was used to compare two
independent groups using GraphPad 5 software. A probability (p)
value of ,0.05 was considered significant. *p,0.05; **p,0.01;
***p,0.001.
Figure 1. BAFF expression and secretion are up-regulated in Poly (I:C)- and IFN-c-stimulated rheumatoid arthritis (RA) fibroblast-
like synoviocytes (FLS) and systemic sclerosis (SSc) human dermal fibroblast (HDF). A, C. BAFF mRNA expression was determined by RT-
qPCR in NFLS(n= 4) and RAFLS(n= 4) (A) or NHDF(n= 3) and SScHDF (n = 4) (C) stimulated (depending of the cell types) with BLP (1 mg/ml), LPS (1 mg/
ml), Poly (I:C) (10 mg/mL) or IFN-c (0.1, 1 or 5 ng/mL) for 72 h. Results were normalized to Gapdh and expressed as fold change compared with
samples from cells incubated in medium. B, D. BAFF release was quantified by ELISA in culture supernatants of NFLS (n = 4) and RAFLS(n = 4) (B) or
NHDF(n = 3) and SScHDF (n = 4) (D) in the same conditions as panels A and C. Data are expressed as the mean of triplicate samples 6 SEM. *p,0.05,
**p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0111266.g001
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Results
Increased BAFF secretion by SScHDF after stimulation
with Poly(I:C) or IFN-c
Upregulation of BAFF expression by Poly (I:C)- and IFN-c-
activated RAFLS, but not upon TLR2 or TLR4 activation, has
been previously reported [13,22]. To gain more insights into the
physiopathological consequences of this observation, we first
compared BAFF expression in FLS isolated from healthy donors
or RA patients. As shown in figure 1A and B, we observed that
IFN-c-dependent BAFF expression reaches maximum levels in
RAFLS, whereas FLS isolated from healthy donors (NFLS) exhibit
reduced cytokine expression at both mRNA and protein levels. Of
note, Poly (I:C) stimulation induced very limited BAFF expression
and secretion by NFLS, while RAFLS appeared extremely
responsive to this stimulus. Next, we tested whether this difference
between a healthy and a pathological (inflammatory) state could
also be observed in another fibroblastic cell type and for this, we
chose Human Dermal Fibroblasts (HDF) isolated from skin
biopsies harvested from healthy donors (NHDF) or from patients
suffering from systemic sclerosis (SScHDF). IFN-c stimulation (1
and 5 ng/mL) resulted in a comparable increased expression of
BAFF transcripts (figure 1C) and cytokine secretion (figure 1D) by
NHDF or SScHDF. Interestingly, up-regulation of BAFF tran-
scripts and protein release in response to TLR3 triggering by Poly
(I:C) was only detectable in SScHDF and not from healthy
individuals. We also investigated here the ability of Bacterial
LipoProteins (BLP, Pam3CSK4) or LipoPolysaccharide (LPS),
which are respectively ligands for TLR2 and 4, to stimulate BAFF
synthesis by NHDF and SScHDF. As seen in figure 1C and D,
these PAMPs (Pathogen Associated Molecular Pattern) are not
activators of BAFF transcription.
Thus, these results show that FLS and HDF from both healthy
donors and RA or SSc patients can produce BAFF in response to
IFN-c stimulation, whereas BAFF transcription and protein
secretion upon Poly (I:C) triggering occurred only in fibroblasts
isolated from RA or SSc patients.
miR-30a-3p is down-regulated in Poly(I:C)- and IFN-c-
activated RAFLS and SScHDF
To understand the mechanisms underlying Poly (I:C)- and IFN-
c-dependent BAFF induction, we then focused our work on
miRNA-driven post-transcriptional regulation. A computer-assist-
ed search for miRNAs predicted to target BAFF mRNA
performed using microCosm (http://www.ebi.ac.uk/enright-srv/
microcosm/htdocs/targets/v5) identified several miRNAs candi-
dates: miR-144*, miR-452, miR-340, miR-202, miR-500, miR-
626, miR-330-3p, miR-302c* and miR-30 family members (miR-
30a, d and e which share the same seed sequence). To evaluate the
possible involvement of these miRNAs in BAFF regulation, we first
performed RT-qPCR analysis to quantify their expression in
RAFLS and SScHDF treated with Poly(I:C) or IFN-c for 6 h, 48 h
and 72 h. This analysis revealed that miR-144*, miR-30d-3p,
miR-340, miR-626, miR-330-3p and miR-302c* could not be
detected in RAFLS and SScHDF (figure 1S). miR-202 and miR-
500 were expressed constitutively but their expression did not
change after activation by Poly(I:C) or IFN-c in both cell type.
Finally, miR-452 was upregulated in Poly (I:C) treated RAFLS.
Figure 2. miR-30a-3p expression is down-regulated in Poly (I:C)- and IFN-c-stimulated RAFLS and SScHDF. A. miR-30a-3p is predicted
to target BAFF 39 UTR mRNA. B, C. miR-30a-3p expression was determined by RT-qPCR in RAFLS (n = 4) (B) and SScHDF (n = 4) (C) stimulated with Poly
(I:C) (10 mg/mL) or IFN-c (0.1 or 5 ng/mL) for 6 h, 48 h and 72 h. Results were normalized to U6snRNA and expressed as fold change compared with
samples from cells incubated in medium. Data are expressed as the mean of triplicate samples 6 SEM. *p,0.05, ***p,0.001.
doi:10.1371/journal.pone.0111266.g002
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Interestingly, we noted that both miR-30a-3p and miR-30e-3p
(data not shown), were significantly down-regulated in Poly (I:C)-
and IFN-c-activated, RAFLS (Figure 2B) and SScHDF (fig-
ure 2C) 48 h and 72 h after stimulation. These data, together
with those illustrated in figure 1, indicate that BAFF transcripts
and miR-30a-3p exhibit opposite expression patterns, therefore
suggesting potential interactions. Given the strong similarities
between miR-30a-3p and miR-30e-3p, we decided to focus on
miR-30a-3p.
miR-30a-3p directly interacts with the 39UTR of BAFF
mRNA
To validate the involvement of miR-30a-3p in the regulation of
BAFF expression, we generated luciferase reporter constructs
(derived from the pSI-CHECK2 vector) containing the firefly
luciferase gene fused to the entire human BAFF 39UTR sequence
and the renilla luciferase for normalization. We also generated a
reporter construct in which a mutated version, designed to disrupt
the predicted seed-match for miR-30a-3p of the human BAFF
39UTR, was inserted (figure 3A). These plasmids were co-
transfected in HEK293 cells with miR-30a-3p mimic or AllStars
negative control siRNA (CT). In the presence of miR-30a-3p
mimic, we observed a significant down regulation of the BAFF
39UTR-controlled luciferase sensor, whereas luciferase expression
upon transfection of the mutated form of the reporter vector
remained unchanged (figure 3B). Altogether, these data suggest
that BAFF transcripts can be directly targeted by miR-30a-3p for
post-transcriptional regulation.
miR-30a-3p modulates BAFF expression in RAFLS and
SScHDF
To assess the effect of miR-30a-3p on BAFF expression, we
measured the production of BAFF mRNA by RT-qPCR in
RAFLS and SScHDF transfected with miR-30a-3p mimic or with
the AllStars negative siRNA control (CT). 24 h after transfection,
cells were stimulated with Poly (I:C) or IFN-c for 72 h. As seen in
Figure 4, we found that overexpression of miR-30a-3p led to a
global decrease in BAFF mRNA production and protein secretion
by Poly (I:C)- and IFN-c-activated RAFLS and SScHDF (panels
A–D). Of note, transfection of miR-30a-3p mimic did not
modulate IL-6 secretion by RAFLS and SScHDF activated with
Poly (I:C) or IFN-c (figure 4E–F), which is another major cytokine
involved in B cells proliferation [23]. This indicates that miR-30a-
3p does not interact with transcripts encoding factors involved in
cytokine expression or inflammatory responses, but rather
specifically interferes with BAFF mRNA in these cells, hence
strengthening a potential role for BAFF in this process. Similar
results were obtained upon transfection of miR-30e-3p and miR-
30d-3p (data not shown).
These data demonstrate that miR-30a-3p is implicated in the
negative regulation of BAFF synthesis in Poly (I:C)- and IFN-c-
activated FLS and HDF.
Figure 3. miR-30a-3p directly targets the 39UTR of BAFF mRNA. A. Luciferase reporter constructs with wild-type or mutated (for miR-30-3p
binding sites) BAFF 39UTR were generated. B. HEK293 cells were transiently co-transfected with reporter constructs and with miR-30a-3p mimic
(20 pM). Firefly Luciferase activities were measured 48 h after transfection and normalized to Renilla Luciferase expressed by the control psi-CHECK-2
vector devoid of 39UTR sequences. Data are expressed as the mean of triplicate samples 6 SEM and are representative of three independent
experiments. **p,0.01.
doi:10.1371/journal.pone.0111266.g003
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miR-30a-3p specifically represses BAFF-dependent B cells
survival
Next, we checked the physiological relevance of BAFF
regulation by miR-30a-3p. To this end, we measured the faculty
of stimulated RAFLS and SScHDF to promote B cells survival
following transfection of miR-30a-3p mimic. RAFLS and
SScHDF were transfected with miR-30a-3p mimic or with the
AllStars negative control siRNA (CT) for 24 h and then activated
with IFN-c for 72 h. The supernatants (conditioned medium) were
harvested and added in the culture medium of B cells. After 3
days, survival of CD19-gated B cells was assessed by FACS
analysis. As shown in figure 5, addition of supernatant from IFN-
c-stimulated fibroblasts significantly (p,0.05) increases the pro-
portion of viable B cells, which shifts from 10 to 26% in the case of
RAFLS supernatant and from 35 to 56% in the case of SScHDF.
Importantly, increasing miRNA activity upon transfection of miR-
30a-3p mimic in activated fibroblasts lowers B cells viability (15%
and 35%, respectively. p,0.05). Additionally, we analyzed the
supernatant of Poly (I:C)-activated RAFLS and SScHDF but we
could not detect any difference in B cells survival (data not shown).
Indeed, Poly (I:C), unlike IFN-c, is also a potent inducer of IL-6
release by RAFLS and SScHDF (figure 4 E–F) which could
Figure 4. miR-30a-3p transfection affects BAFF mRNA expression and BAFF secretion in RAFLS and SScHDF. A, C. RAFLS (n = 5) (A) and
SScHDF (n = 4) (C) were transfected with miR-30a-3p mimic (20 pM/sample) or with an AllStars negative control (CT). After 24 h, cells were activated
with Poly (I:C) (10 mg/mL), IFN-c (0.1 or 5 ng/mL, depending on cell types) or medium for 72 h. BAFF mRNA expression was determined by RT-qPCR.
Results were normalized to Gapdh and expressed as fold change compared with samples from cells incubated with medium. B, D. BAFF release was
determined by ELISA in culture supernatants in the same conditions as panel A and C. E, F. IL-6 release was determined by ELISA in culture
supernatants in the same conditions as panel A and C. Data are expressed as the mean of triplicate samples 6 SEM. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0111266.g004
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regulate B cells survival. Similar results were obtained upon
transfection of miR-30e-3p and miR-30d-3p (data not shown).
This experiment reveals that the modulation of miR-30a-3p
activity induces important physiological changes with potentially
relevant immune repercussions within the frame of autoimmune
diseases.
miR-30a-3p is a basal repressors of BAFF expression in
non-inflammatory fibroblasts (NFLS and NHDF)
Finally, we considered the possibility that miR-30a-3p family
members could represent an essential mechanism to maintain
BAFF expression at a very low level necessary in healthy
conditions. Indeed, excessive BAFF secretion leading to increased
B cells activation constitutes a major trigger promoting auto-
immunity. A first insight into this model is provided by our initial
observation of augmented BAFF secretion in the supernatant of
RAFLS compared to NFLS in response to Poly(I:C) and IFN-c
(figure 1B). Therefore, we compared the expression of miR-30a-
3p between healthy donor and patients cells in response to
Poly(I:C) and IFN-c for 48 h and 72 h. Interestingly, we showed
that control NFLS as well as Poly(I:C)- and IFN-c-stimulated cells
expressed higher levels of miR-30a-3p compared to RAFLS under
the same conditions (figure 6A). Moreover, NHDF which did not
release BAFF in response to Poly(I:C) (figure 1D), also expressed
higher levels of miR-30a-3p in the same conditions (figure 6B).
These observations strongly suggest that miR-30a-3p could be a
basal repressor of BAFF expression in these cells. Similar results
were obtained upon transfection of miR-30e-3p (data not shown).
To test this hypothesis, we next lowered the activity of miR-30a-
3p by transfecting specific antagonists (antisense 29O methylated
oligoribonucleotides) or negative controls (CT) in NFLS and
NHDF. 24 h after transfection, cells were stimulated with
Poly(I:C) or IFN-c for 72 h. As illustrated in figure 6C, treatment
with Poly(I:C) significantly induced higher levels of BAFF release
by activated NHDF transfected with antisense oligonucleotides
targeting miR-30a-3p compared to activated NHDF transfected
with control (CT) (113,15623,75 vs 30,7563,25 pg/ml). A similar
increase in BAFF secretion was obtained in NFLS transfected with
antisense oligonucleotides targeting miR-30a-3p stimulated with
Poly(I:C) (122622 vs 38,265,5 pg/ml) and IFN-c (109,45620,85
vs 29,6564,85 pg/ml). This experiment suggests that miR-30a-3p
could represent an essential mechanism to maintain BAFF
expression at a very low level necessary in healthy conditions.
Moreover, we checked whether BAFF transcripts modulation
upon miR-30a-3p inhibition also positively impacts on B cells
survival. For this, we added anti-BAFF antibodies to poly (I:C)-
stimulated NHDF treated with miR-30-3p antagomiRs. As seen in
figure 6D, addition of anti-BAFF antibodies significantly (p,0.01
**) eradicates miR-30a-dependant-B cells survival improvement,
thereby demonstrating that miR-30a-3p specifically modulates
BAFF expression.
Discussion
The role of B cells in autoimmunity has undergone a major
renaissance after the demonstration of the efficacy of B cells
depletion in RA [24]. BAFF plays a pivotal role in B cells
activation in autoimmune diseases and is secreted by resident cells
of target organs such as fibroblast-like synoviocytes [22,25,26]. On
the other hand, the pivotal role of innate immunity in the initiation
of autoimmune diseases is now well established, which prompted
our present investigation on the role of innate immune receptors
ligands and interferon-c on BAFF secretion. We performed our
analysis in fibroblasts isolated either from the skin (HDF) of
healthy donors or from patients suffering from SSc or from the
synovium (FLS) of RA patients or controls. Our results clearly
show that, while Poly (I:C) stimulation induces high levels of BAFF
transcription, LPS or BLP (respectively ligands of TLR4 and
TLR2) remain poor activators of BAFF expression and secretion.
Likewise, Poly (I:C) as well as LPS or BLP did not induce the
synthesis of APRIL (a proliferation inducing ligand), which
regulates also lymphocyte survival and activation (data not shown).
Figure 5. miR-30a-3p expression in RAFLS and SScHDF regulates BAFF-dependent B cells survival in vitro. RAFLS (n = 4) (left) and
SScHDF (n = 4) (right) were transfected with miR-30a-3p mimic (20 pM/sample) or with an AllStars negative control (CT). After 24 h, cells were
activated with IFN-c (0.1 or 5 ng/mL depending on the cell type) or medium for 72 h. Then, supernatants were harvested and cultured with purified
blood B cells isolated from healthy subjects. B cells viability was determined by FACS analysis; vital B cells were brightly positive when stained with
DiOC6 and excluded PI. Data are expressed as the mean of triplicate samples 6 SEM. *p,0.05.
doi:10.1371/journal.pone.0111266.g005
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This finding is consistent with results from our group which
proposed that TLR2, 4 and 9 ligands failed to induce BAFF
mRNA and protein in rheumatoid FLS [22]. Likewise, stimulation
of salivary gland epithelial cells (SGEC) obtained from patients
with primary Sjo¨gren’s syndrome (pSS) or bronchial epithelial cells
with TLR2, 7 and 9 ligands does not induce BAFF transcription
and secretion [27,28]. Therefore, a first important result of this
study is our description of specific Poly (I:C)-dependent BAFF
transcriptional induction and subsequent secretion by SScHDF.
This observation provides a conceptual framework whereby
pathogens, such as herpesviruses which are capable of triggering
a TLR3-dependent response [29] and have been associated to
many autoimmune diseases [30], can initiate BAFF secretion and
ignite a vicious circle leading to pathogenic auto-antibodies
production. In line with this hypothesis, Ittah et al. suggested that
PKR is the major mediator of BAFF expression and secretion after
dsRNA virus infection or Poly (I:C) stimulation by salivary
epithelial cells of pSS [31].
Next, we investigated the mechanisms involved in the regulation
of BAFF production by FLS and HDF. miRNAs, which are
considered as efficient fine tuners of immune responses because
they usually modulate gene expression by a factor 1.2 to 4 [32],
exhibit abnormal expression associated with inflammatory disor-
ders such as RA [33,34], SLE [35,36] and SSc [37,38]. In an
initial attempt to identify miRNAs involved in the control of BAFF
expression, we performed RT-qPCR analysis of Poly (I:C)- and
IFN-c-activated RAFLS and SScHDF to quantify the expression
of 9 miRNAs that were predicted to target BAFF transcripts.
Among these candidates, miR-30a-3p was selected for further
analysis because its expression was down regulated in Poly (I:C)-
and IFN-c-activated RAFLS and SScHDF; such inverse correla-
tion with the expression of BAFF transcripts in the same cells and
the same conditions indicated that miR-30-3p family members
might have a role in the regulation of BAFF expression. We next
demonstrated by several complementary approaches that miR-
30a-3p actually bind specifically to the 39UTR of BAFF transcripts
and modulate cytokine expression. Importantly, additional results
(data not shown) indicate that additional members (and closely
related) of the miR-30a-3p family (miR30-d-3p and -e-3p) also
regulate BAFF expression in RAFLS and SScHDF stimulated with
Poly (I:C) or IFN-c. Therefore, our study additionally suggests a
novel mechanism for the regulation of BAFF expression at the
posttranslational level in response to inflammatory stimuli but the
transcriptional regulation of BAFF expression must also be
considered. Usually, miRNAs can function together with RNA-
binding proteins to regulate mRNA expression through the AU-
Figure 6. MiR-30a-3p represses BAFF secretion by healthy FLS and HDF. A, B. miR-30a-3p expression was determined by RT-qPCR in NFLS
(n = 4)/RAFLS (n = 4) (A) and NHDF (n = 3)/SScHDF (n = 4) (B) stimulated with Poly(I:C) (10 mg/mL), IFN-c (0.1 or 5 ng/mL) or medium for 48 h and 72 h.
Results were normalized to U6snRNA and expressed as fold change compared with samples from RAFLS (A) or SScHDF (B) incubated with medium. C.
NFLS (n = 3) and NHDF (n = 3) were transfected with miR-30-3p antisense oligonucleotides (20 pM/sample) or with an AllStars negative control (CT).
After 24 h, cells were activated with Poly(I:C) (10 mg/mL), IFN-c (0.1 or 5 ng/mL) or medium for 72 h. BAFF release was determined by ELISA in culture
supernatants. D. NHDF (n = 3) transfected with miR-30-3p antisense, were stimulated with poly (I:C). The supernatant was then treated with control
IgG or with anti-BAFF antibodies and added to purified B cells. B cells survival was next evaluated as in panel Figure 5. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0111266.g006
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rich elements (AREs) that are found in numerous cytokine-
encoding mRNAs. For example, TNF-a and IL-10 mRNAs both
contain long AREs that are targeted by the RNA-binding protein
tristetraprolin (TTP) [39]. Our group previously showed that
blocking miR-346 decreases TTP expression and re-established
mature TNF-a intracellular expression in LPS-activated RAFLS
[40,41]. Although evidence for the direct targeting of cytokine
mRNAs by miRNAs is limited [39], we demonstrated in this study
that miR 30a-3p directly regulates BAFF mRNA.
Importantly, we also analyzed in our study the functional
outcome of miRNA-dependent BAFF regulation. We demonstrat-
ed that IFN-c stimulation of fibroblasts favors an extracellular
milieu that promotes B cells survival. Importantly, our experi-
ments (illustrated in Figure 5) demonstrated that specifically
altering BAFF secretion (with miR-30a mimic or upon anti-BAFF
antibodies addition following antagomiRs transfection) reduces the
B cells survival capacity of supernatant from IFN-c stimulated
RAFLS or SScHDF back to normal (as observed in control cells).
This indicates that BAFF (and not IL-6) is the major B cells
survival factor expressed by these fibrocytes upon IFN-c stimula-
tion. Similar to our findings, Ohata et al reported that FLS treated
with IFN-c and/or TNF-a had a greater capacity to support B
cells survival than did untreated FLS [26]. B cells survival could be
inhibited by BAFF-R:Fc, indicating that BAFF/BAFF-R interac-
tions were involved in B cells survival [26]. Altogether, this work
provides a mechanistic explanation to the control of BAFF
transcripts expression and demonstrates that cytokine secretion by
resident cells of target organs of autoimmune diseases can be
negatively regulated at the post-transcriptional level by miRNAs.
A tentative model describing these interactions is depicted in
Figure 2S. The understanding of these complex pathways has
important implications for the development of future therapeutic
applications. Indeed, the success of Belimumab in the treatment of
patients with RA and ongoing clinical trials in SSc
(NCT01670565) suggest that therapeutic targeting of BAFF could
be of interest [42]. Our present study suggests that miR-30a-3p
(and others family members) mimic could be used to target BAFF
mRNA in autoimmune diseases. Recently, patients chronically
infected with hepatitis C virus (HCV) treated with locked nucleic
acid (modified antisense oligonucleotides) against miR-122 showed
a prolonged dose-dependent reductions in HCV RNA levels
without evidence of viral resistance [43], which suggests that
miRNA modulation in patients could become a new therapeutic
option in the future.
Supporting Information
Figure S1 miRNAs expression in RAFLS and SScHDF.
MiR-144*, miR-30d-3p, miR-452, miR-340, miR-202,
miR-500, miR-626, miR-330-3p and miR-302c* expres-
sion was determined by RT-qPCR in RAFLS (n=3) and
SScHDF (n=3) stimulated with Poly (I:C) (10 mg/mL) or
IFN-c (0.1 or 5 ng/mL) for 72 h. Results were normalized to
U6snRNA and expressed as fold change compared with samples
from RAFLS or SScHDF incubated with medium.
(TIFF)
Figure S2 Model describing the role of miR-30a-3p in
BAFF secretion by FLS (A) and HDF (B) from RA or SSc
patients and healthy subjects.
(TIFF)
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